NICE recommends cannabis based drugs for epilepsy and multiple sclerosis
BMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l6453 (Published 11 November 2019) Cite this as: BMJ 2019;367:l6453Linked Opinion
New guidelines for prescribing medicinal cannabis—another dashed hope for patients
- Elisabeth Mahase
- The BMJ
In final appraisal documents the UK National Institute for Health and Care Excellence has recommended the use of cannabidiol with clobazam for treating seizures associated with two rare and severe forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.12
The decision comes after NICE initially rejected the use of cannabidiol in draft appraisal documents released in August because of concerns over a lack of data on the drug’s long term effectiveness.3
However, in its latest documents NICE has recommended the drug for people aged 2 or over, reporting …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.